Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Mainz Biomed BV (MYNZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: MYNZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -36.37% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.42M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 211965 | Beta 0.32 | 52 Weeks Range 3.65 - 45.20 | Updated Date 03/23/2025 |
52 Weeks Range 3.65 - 45.20 | Updated Date 03/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -44.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1883.22% |
Management Effectiveness
Return on Assets (TTM) -99.24% | Return on Equity (TTM) -4333.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 16778432 | Price to Sales(TTM) 9.61 |
Enterprise Value 16778432 | Price to Sales(TTM) 9.61 | ||
Enterprise Value to Revenue 18.29 | Enterprise Value to EBITDA -2.84 | Shares Outstanding 2221600 | Shares Floating 540766 |
Shares Outstanding 2221600 | Shares Floating 540766 | ||
Percent Insiders 4.98 | Percent Institutions 11.05 |
Analyst Ratings
Rating 3 | Target Price 2 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Mainz Biomed BV
Company Overview
History and Background
Mainz Biomed NV is a molecular genetics diagnostic company specializing in the research and development of innovative, cost-effective products for early detection of cancers. Founded with a focus on colorectal cancer (CRC) screening.
Core Business Areas
- Colorectal Cancer Screening: Develops and commercializes CRC screening tests based on fecal DNA analysis.
- Gastrointestinal Disease Diagnostics: Expanding portfolio to include diagnostic solutions for other gastrointestinal diseases.
Leadership and Structure
The company has a management team with expertise in molecular diagnostics, oncology, and commercialization. Operates with a board of directors overseeing strategy.
Top Products and Market Share
Key Offerings
- ColoAlert: A non-invasive, at-home CRC screening test based on fecal DNA. Competitors include Exact Sciences (EXAS) with Cologuard. Market share information specific to ColoAlert's US market is difficult to determine, but Mainz Biomed is actively pursuing market entry.
Market Dynamics
Industry Overview
The market for CRC screening is growing, driven by increasing awareness, aging populations, and the desire for less invasive screening methods.
Positioning
Mainz Biomed aims to compete in the CRC screening market by offering a convenient and accurate alternative to traditional methods like colonoscopy. Key competitive advantage is its non-invasive at home test.
Total Addressable Market (TAM)
The global CRC screening market is estimated to be billions of dollars. Mainz Biomed is positioned to capture a portion of this market through its ColoAlert and future product offerings.
Upturn SWOT Analysis
Strengths
- Non-invasive testing method
- High sensitivity and specificity (claimed)
- At-home convenience
- Strong scientific team
Weaknesses
- Limited commercial presence in the US currently
- Requires regulatory approvals (FDA)
- Relatively new entrant compared to established players
- Market penetration depends on reimbursement coverage
Opportunities
- Expanding CRC screening market
- Partnerships with healthcare providers and payers
- Further product development and innovation
- Geographic expansion
Threats
- Competition from established players (EXAS)
- Changes in regulatory landscape
- Adverse clinical trial results
- Pricing pressures
Competitors and Market Share
Key Competitors
- EXAS
Competitive Landscape
Mainz Biomed is a smaller player in the CRC screening market compared to Exact Sciences. It aims to differentiate itself through its technology and convenience.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Mainz Biomed's historical growth has been focused on product development and clinical trials.
Future Projections: Future growth is dependent on regulatory approvals, commercialization success, and market acceptance of ColoAlert.
Recent Initiatives: Focus is on US market entry, pursuing FDA approval for ColoAlert, and expanding testing capabilities.
Summary
Mainz Biomed is a developing company in the CRC screening market with promising technology. Success relies heavily on FDA approval and successful commercialization of ColoAlert in the US. Competition is fierce, requiring strategic partnerships to achieve growth. The current market conditions provide an opportunity for their product, but significant market penetration is vital to financial stability.
Similar Companies
- EXAS
- NVGN
Sources and Disclaimers
Data Sources:
- Company website
- Company press releases
- SEC filings
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investments in Mainz Biomed NV are speculative and involve a high degree of risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mainz Biomed BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | CEO & Executive Director Mr. Guido Baechler | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 65 | Website https://mainzbiomed.com |
Full time employees 65 | Website https://mainzbiomed.com | ||
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.